Dutch Statutory Annual Report

Overview

The report presents InflaRx as a biopharmaceutical group focused on anti-C5a/C5aR therapeutics. For 2025, it reports consolidated revenue of €29,331 from GOHIBIC sales. Phase 2a data covered 29 HS patients and 30 CSU patients, with no safety signal of concern reported in either indication. The sustainability section states that its assessment and objectives were not yet formalized.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services